Background Obese patients are underrepresented in clinical trials assessing the
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …

Background Guidance for dabigatran and rivaroxaban in overweight patients diagnosed
with non-valvular atrial fibrillation (NVAF) is still lacking. Aim Compare the effectiveness and …

Real-world studies have evaluated the use of anticoagulants in obese patients with
nonvalvular atrial fibrillation (NVAF), but they have been limited by sample size or the use of …

Background: Direct oral anticoagulants (DOACs) have been increasingly preferred over
warfarin; however, The International Society of Thrombosis and Hemostasis recommended …

Study Objective Patients with nonvalvular atrial fibrillation (NVAF) often have multiple
comorbidities requiring concomitant medications in addition to their oral anticoagulant …

Background Considering that the current fixed dose of direct oral anticoagulants (DOACs)
might have insufficient anticoagulation effect for overweight patients, the aim of this study …

Abstract Purpose Factor Xa Inhibitors have emerged as a first-line agent in the management
of non-valvular atrial fibrillation (NVAF), but there is a need for additional data surrounding …

Background: Rivaroxaban was shown to be effective in reducing the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (AF) in a randomized …

Purpose Compared with warfarin, the new target-specific oral anticoagulant agents may
have advantages, such as shorter hospital length of stay, in patients with nonvalvular atrial …

Background: Limited clinical data exist describing the use of direct-acting oral
anticoagulants (DOACs) in patients with body mass index (BMI)> 40 kg/m2 or body weight> …